# Lorlatinib Renal Impairment Study

> **NCT03542305** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 29 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT03542305
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-23
- **Primary completion:** 2020-02-20
- **Final completion:** 2020-02-20
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03542305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03542305, "Lorlatinib Renal Impairment Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03542305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*